Portfolio companies news

20 April 2015

Range of ‘uninterrupted vision’ possible with inlay

Michelle Dalton / Ophthalmology Times

Study patients with a near vision inlay implanted under a femtosecond flap achieved extended depth of focus that ranged from +1 to +3 D, said John A. Hovanesian, MD. The implant (Raindrop Near Vision Inlay, ReVision Optics) is designed to change the curvature of the overlying cornea creating a gradient of power that allows a full range of uninterrupted vision.

16 April 2015

Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells

Epic Sciences announced today that its no cell left behind™ technology has successfully integrated single cell isolation and downstream genetic analysis of circulating tumor cells (CTCs) to the platform's capabilities. 

15 April 2015

Atlas Genetics Enters Into Diagnostic Collaboration With a Major Pharmaceutical Company

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

13 April 2015

Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat

Neothetics, Inc.  (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2 of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

31 March 2015

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

Syndax Pharmaceuticals, Inc., and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. 

27 March 2015

Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results

Neothetics, Inc.(Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the fourth quarter and year ended December 31, 2014.

25 March 2015

Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy

Marinus Pharmaceuticals, Inc.(Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, for the treatment of protocadherin 19 gene (PCDH19) female epilepsy. 

23 March 2015

Neothetics Initiates Study to Evaluate Safety of Retreatment With LIPO-202 for Body Contouring

Neothetics, Inc.  (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced it has initiated an open-label study to evaluate the safety of multiple courses of treatment of LIPO-202 (salmeterol xinafoate for injection) for the reduction of central abdominal bulging. 

16 March 2015

Clearside Biomedical, Inc. Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the efficacy and safety results from Clearside’s recently completed six-month Phase 1/2 clinical trial.

12 March 2015

Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the year ended December 31, 2014.